老虎证券

GSK Expects 2025 Turnover Growth Of 3%-5%, Core EPS Rise Of 6%-8%, And Core Operating Profit Growth Of 6%-8%

Benzinga
2025/02/05

2025 Guidance 

GSK provides its full-year guidance at constant exchange rates (CER). 

  • Turnover is expected to increase between 3 to 5 per cent 
  • Core operating profit is expected to increase between 6 to 8 per cent 
  • Core earnings per share is expected to increase between 6 to 8 per cent 

This guidance is supported by the following turnover expectations for full-year 2025 at CER 

  • Specialty Medicines – expected increase of a low double-digit per cent in turnover 
  • Vaccines – expected decrease of a low single-digit per cent in turnover 
  • General Medicines – expected to be broadly stable for turnover

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10